Total Payments
$93,464
2024 Payments
$98.58
Companies
13
Transactions
118
Medicare Patients
142
Medicare Billing
$9,475
Payment Breakdown by Category
Consulting$48,187 (51.6%)
Research$35,834 (38.3%)
Travel$7,252 (7.8%)
Food & Beverage$2,132 (2.3%)
Education$58.91 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $48,187 | 9 | 51.6% |
| Unspecified | $35,834 | 36 | 38.3% |
| Travel and Lodging | $7,252 | 33 | 7.8% |
| Food and Beverage | $2,132 | 37 | 2.3% |
| Education | $58.91 | 3 | 0.1% |
Payments by Type
General
$57,630
82 transactions
Research
$35,834
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $30,705 | 37 | $0 (2019) |
| Circassia Pharmaceuticals Inc | $30,674 | 9 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $14,105 | 21 | $0 (2021) |
| GlaxoSmithKline, LLC. | $9,312 | 13 | $0 (2017) |
| OptiNose US, Inc. | $3,814 | 8 | $0 (2020) |
| AstraZeneca UK Limited | $1,704 | 7 | $0 (2018) |
| SANOFI US SERVICES INC. | $1,377 | 16 | $0 (2018) |
| BioCryst Pharmaceuticals, Inc. | $1,375 | 1 | $0 (2020) |
| Imperative Care, Inc | $125.08 | 1 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $114.92 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98.58 | 1 | AstraZeneca Pharmaceuticals LP ($98.58) |
| 2022 | $125.08 | 1 | Imperative Care, Inc ($125.08) |
| 2021 | $2,131 | 1 | Regeneron Pharmaceuticals, Inc. ($2,131) |
| 2020 | $2,776 | 4 | BioCryst Pharmaceuticals, Inc. ($1,375) |
| 2019 | $13,873 | 21 | Regeneron Healthcare Solutions, Inc. ($10,743) |
| 2018 | $26,455 | 54 | Regeneron Healthcare Solutions, Inc. ($11,980) |
| 2017 | $48,006 | 36 | Circassia Pharmaceuticals Inc ($30,674) |
All Payment Transactions
118 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $98.58 | General |
| 06/07/2022 | Imperative Care, Inc | ZOOM REPERFUSION CATHETER (Device), ZOOM 88-T LARGE DISTAL PLATFORM | Food and Beverage | In-kind items and services | $125.08 | General |
| Category: VASCULAR | ||||||
| 08/16/2021 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $2,131.04 | Research |
| Study: A STUDY TO EVALUATE THE EFFICACY OF DUPILUMAB AS AN ADJUNCT FOR SUBCUTANEOUS GRASS IMMUNOTHERAPY TO REDUCE PROVOKED ALLERGIC RHINITIS SYMPTOMS USING THE NASAL ALLERGEN CHALLENGE MODEL • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/13/2020 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| 06/25/2020 | OptiNose US, Inc. | Xhance (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 06/06/2020 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $347.36 | Research |
| Study: A STUDY TO EVALUATE THE EFFICACY OF DUPILUMAB AS AN ADJUNCT FOR SUBCUTANEOUS GRASS IMMUNOTHERAPY TO REDUCE PROVOKED ALLERGIC RHINITIS SYMPTOMS USING THE NASAL ALLERGEN CHALLENGE MODEL • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/01/2020 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $253.20 | Research |
| Study: A STUDY TO EVALUATE THE EFFICACY OF DUPILUMAB AS AN ADJUNCT FOR SUBCUTANEOUS GRASS IMMUNOTHERAPY TO REDUCE PROVOKED ALLERGIC RHINITIS SYMPTOMS USING THE NASAL ALLERGEN CHALLENGE MODEL • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/16/2019 | OptiNose US, Inc. | Xhance (Drug) | Travel and Lodging | Cash or cash equivalent | $180.26 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 05/03/2019 | OptiNose US, Inc. | Xhance (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/26/2019 | OptiNose US, Inc. | Xhance (Drug) | Travel and Lodging | In-kind items and services | $186.67 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/26/2019 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $49.26 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/26/2019 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/26/2019 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $34.04 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/26/2019 | OptiNose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 04/01/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $6,080.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/01/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,040.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/01/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $82.28 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/14/2019 | Teva Pharmaceuticals USA, Inc. | Fluticasone Propionate and Salmeterol (Drug) | — | Cash or cash equivalent | $114.92 | Research |
| Study: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma • Category: Respiratory | ||||||
| 03/13/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $216.64 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/13/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $79.35 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/13/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $67.13 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/13/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $45.34 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/05/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $84.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/04/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $123.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/28/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $434.33 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | Circassia Pharmaceuticals Inc | $15,776 | 4 |
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $14,898 | 5 |
| A STUDY TO EVALUATE THE EFFICACY OF DUPILUMAB AS AN ADJUNCT FOR SUBCUTANEOUS GRASS IMMUNOTHERAPY TO REDUCE PROVOKED ALLERGIC RHINITIS SYMPTOMS USING THE NASAL ALLERGEN CHALLENGE MODEL | Regeneron Pharmaceuticals, Inc. | $2,732 | 3 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 | SANOFI US SERVICES INC. | $1,377 | 16 |
| A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model | Regeneron Pharmaceuticals, Inc. | $937.35 | 7 |
| A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | Teva Pharmaceuticals USA, Inc. | $114.92 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 49 | 65 | $15,007 | $3,048 |
| 2022 | 2 | 43 | 52 | $11,616 | $2,445 |
| 2021 | 1 | 26 | 35 | $9,800 | $2,518 |
| 2020 | 1 | 24 | 28 | $7,448 | $1,463 |
Total Patients
142
Total Services
180
Medicare Billing
$9,475
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 42 | $13,213 | $2,912 | 22.0% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 18 | 23 | $1,794 | $136.46 | 7.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 35 | $10,290 | $2,339 | 22.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 14 | 17 | $1,326 | $106.15 | 8.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 26 | 35 | $9,800 | $2,518 | 25.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 24 | 28 | $7,448 | $1,463 | 19.6% |
About Dr. Mark Moss, MD
Dr. Mark Moss, MD is a Pediatric Allergy/Immunology healthcare provider based in Madison, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093781163.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Moss, MD has received a total of $93,464 in payments from pharmaceutical and medical device companies, with $98.58 received in 2024. These payments were reported across 118 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($48,187).
As a Medicare-enrolled provider, Moss has provided services to 142 Medicare beneficiaries, totaling 180 services with total Medicare billing of $9,475. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Allergy/Immunology
- Other Specialties Allergy
- Location Madison, WI
- Active Since 02/27/2006
- Last Updated 01/14/2021
- Taxonomy Code 2080P0201X
- Entity Type Individual
- NPI Number 1093781163
Products in Payments
- DUPIXENT DUPILUMAB INJECTION (Biological) $31,336
- DUPIXENT (Biological) $13,475
- Xhance (Drug) $3,814
- FASENRA (Drug) $1,704
- NUCALA (Biological) $1,464
- SAR440340 (Drug) $1,377
- ZOOM REPERFUSION CATHETER (Device) $125.08
- Fluticasone Propionate and Salmeterol (Drug) $114.92
- CINRYZE (Drug) $37.65
- ALVESCO (Drug) $21.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Allergy/Immunology Doctors in Madison
Sameer Mathur, Md Phd, MD PHD
Pediatric Allergy/Immunology — Payments: $299,444
Pediatric Allergy/Immunology $299,444
James Gern, Md, MD
Pediatric Allergy/Immunology — Payments: $269,003
Pediatric Allergy/Immunology $269,003
Dr. Daniel Jackson, M.d, M.D
Pediatric Allergy/Immunology — Payments: $187,340
Pediatric Allergy/Immunology $187,340
Robert Lemanske, Md, MD
Pediatric Allergy/Immunology — Payments: $18,402
Pediatric Allergy/Immunology $18,402
Anne Marie Singh, M.d, M.D
Pediatric Allergy/Immunology — Payments: $12,720
Pediatric Allergy/Immunology $12,720
Sima Ramratnam, M.d, M.D
Pediatric Allergy/Immunology — Payments: $4,714
Pediatric Allergy/Immunology $4,714